MEDVi's Telehealth Service Expands Access to GLP-1 Weight-Loss Drugs Like Semaglutide

Obesity remains a growing health issue in the US, with many struggling to find long-term medical support. MEDVi, a telehealth service, now offers physician-supervised weight-loss treatment using GLP-1 drugs like semaglutide and tirzepatide. The programme combines virtual consultations, compounded medications, and ongoing clinical follow-ups to improve access and affordability.

MEDVi's process starts with a digital health assessment, followed by a virtual consultation with a licensed doctor or nurse practitioner. These professionals evaluate whether GLP-1 therapy is medically suitable for the patient. If approved, prescriptions for compounded versions of semaglutide or tirzepatide are issued, particularly when brand-name drugs are scarce or too expensive.

The company partners with US-licensed compounding pharmacies that meet strict federal and state standards, including USP <795>/<797> compliance and sterility testing. Since 2020, expanded telehealth rules under the CARES Act and COVID-era flexibilities have allowed cross-state prescribing without in-person visits, though states like California now enforce tighter controls on compounding. MEDVi ensures prescriptions are filled only by 503A/503B-licensed facilities, avoiding mass production of unregulated compounds.

Once treatment begins, patients receive dosage instructions and regular telehealth check-ins. Providers monitor side effects, adjust doses, and track patient-reported outcomes to maintain safety and compliance. The service operates on a cash-pay basis, cutting insurance hurdles and reducing out-of-pocket costs for those who qualify.

Physician oversight remains central, with medical decisions following state and federal laws. Patients must fully disclose their medical history and report any changes in symptoms during treatment. This structured approach aims to balance accessibility with clinical responsibility.

MEDVi's model combines telehealth convenience with regulated compounding to expand access to GLP-1 weight-loss drugs. By removing insurance barriers and enforcing strict medical supervision, the service targets long-standing gaps in obesity treatment. The programme's success will depend on ongoing compliance with evolving federal and state pharmacy regulations.